JAZZ
Jazz Pharmaceuticals PLC
240.70$
-1.3%
vs. previous close
Closing price · As of: Sep 18, 2026
Investor relations
Report Dates
Investor relations overview for Jazz Pharmaceuticals PLC (JAZZ): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 11/04/2026.
Next report
11/04/2026
Last report
08/03/2026
EPS estimate beaten
Full history
46 of 77 quarters (60%)
Last 16 quarters
8 of 16 quarters (50%)
Earnings Call Transcripts
- 08/03/2026 Earnings Call Q2 2026 Open →
- 05/05/2026 Earnings Call Q1 2026 Open →
- 02/25/2026 Earnings Call Q4 2025 Open →
- 11/05/2025 Earnings Call Q3 2025 Open →
- 08/06/2025 Earnings Call Q2 2025 Open →
- 05/06/2025 Earnings Call Q1 2025 Open →
- 02/25/2025 Earnings Call Q4 2024 Open →
- 11/06/2024 Earnings Call Q3 2024 Open →
- 07/31/2024 Earnings Call Q2 2024 Open →
- 05/01/2024 Earnings Call Q1 2024 Open →
News on This Stock
- 09/15/2026 Jazz Pharmaceuticals plc (JAZZ): Regulation FD Disclosure · sec.gov Open ↗
- 08/31/2026 Jazz Pharmaceuticals plc (JAZZ): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Unregistered Sales of Equity Securities; Other Events; Financial Statements and Exhibits · sec.gov Open ↗
- 08/25/2026 Jazz Pharmaceuticals plc (JAZZ): Other Events · sec.gov Open ↗
- 08/10/2026 Jazz Pharmaceuticals plc (JAZZ): Entry into a Material Definitive Agreement; Financial Statements and Exhibits · sec.gov Open ↗
- 08/10/2026 Jazz Pharmaceuticals plc (JAZZ): Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗
- 08/03/2026 Jazz Pharmaceuticals plc (JAZZ): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗
- 07/24/2026 Jazz Pharmaceuticals plc (JAZZ): Submission of Matters to a Vote of Security Holders · sec.gov Open ↗
Automatically matched wire and portal stories; external links open the original source.
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.